跳至主要内容
临床试验/NCT05888454
NCT05888454Unknown不适用

Dando Pasos Juntos: An Integrative Group Program for Type 2 Diabetes Mellitus

TecSalud Investigación Clínica4 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2023年7月24日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
120
试验地点
4
主要终点
HbA1c levels (%)

研究概览

简要总结

This is an open, randomized, controlled trial to determine the impact of an integrative group program on metabolic control and wellbeing perception of patients with T2DM. The integrative group program consists of 6 in-person sessions directed by a health coach and occurring every other week, and 6 asynchronous educative sessions during a period of 12 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • T2DM diagnosis of less than 5 years
  • Age 18 to 80 years
  • Current residence in Nuevo León, México
  • Availability to attend in-person sessions
  • Provides written informed consent
  • Able to read and write

排除标准

  • Currently under insulin treatment
  • T2DM diagnosis more than 5 years ago
  • Comorbidities such as active cancer, acquired immunodeficiency (HIV+, AIDS), liver, cardiovascular, renal, pulmonary or thyroid disease.
  • History of severe neurologic or psychiatric disease (current or past diagnosis)
  • Currently pregnant or intention of pregnancy in the following 3 months
  • Males that consume more than 4 alcoholic beverages daily or 14 weekly
  • Females that consume more than 3 alcoholic beverages daily or 7 weekly
  • Consumption of any illicit drug

研究组 & 干预措施

Experimental Group

Experimental

Conventional treatment for T2DM + Integrative Group Program

干预措施: Integrative Group Program (Other)

Experimental Group

Experimental

Conventional treatment for T2DM + Integrative Group Program

干预措施: Conventional treatment for T2DM (Other)

Control Group

Active Comparator

Conventional treatment for T2DM

干预措施: Conventional treatment for T2DM (Other)

结局指标

主要结局

HbA1c levels (%)

时间窗: Baseline to 12 weeks

次要结局

  • Fasting insulin (mU/mL)(Baseline to 12 weeks and 36 weeks)
  • High-sensitivity C-reactive protein (hs-CRP, mg/dL)(Baseline to 12 weeks and 36 weeks)
  • HbA1c levels (%)(Baseline to 12 weeks and 36 weeks)
  • Fasting glucose (mg/dL)(Baseline to 12 weeks and 36 weeks)
  • Change in lifestyle instrument(Baseline to 12 weeks and 36 weeks)
  • Homeostatic Model Assessment (HOMA index)(Baseline to 12 weeks and 36 weeks)
  • Subjective sense of wellbeing instrument(Baseline to 12 weeks and 36 weeks)
  • Adherence to pharmacological interventions for T2DM(Baseline to 12 weeks and 36 weeks)
  • Change in dose of pharmacological interventions for T2DM(Baseline to 12 weeks and 36 weeks)

研究者

发起方
TecSalud Investigación Clínica
申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

Integrative Group Program for Type 2 Diabetes... | 临床试验